Choice of NSAID and Management Strategy in Rheumatoid Arthritis and Osteoarthritis
- 1 January 1998
- journal article
- Published by Springer Nature in PharmacoEconomics
- Vol. 14 (2) , 191-199
- https://doi.org/10.2165/00019053-199814020-00007
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- THE COST OF RHEUMATOID ARTHRITISRheumatology, 1996
- Is There Scope for Improving the Cost-Effective Prescribing of Nonsteroidal Anti-Inflammatory Drugs?PharmacoEconomics, 1996
- Problems of using modelling in the economic evaluation of health careHealth Economics, 1996
- Morbidity and treatment in elderly patients surviving hospital admission with bleeding peptic ulcer.Gut, 1995
- Efficacy of nabumetone versus diclofenac, naproxen, ibuprofen, and piroxicam in osteoarthritis and rheumatoid arthritisThe American Journal of Medicine, 1993
- Safety experience with nabumetone versus diclofenac, naproxen, ibuprofen, and piroxicam in osteoarthritis and rheumatoid arthritisThe American Journal of Medicine, 1993
- Pharmacoeconomics of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)PharmacoEconomics, 1993
- Audit of mortality in upper gastrointestinal bleedingPostgraduate Medical Journal, 1989
- Mortality in patients with haematemesis and melaena: a prospective study.BMJ, 1979
- STUDY OF FACTORS INFLUENCING MORTALITY-RATES FROM GASTROINTESTINAL HEMORRHAGE1976